[{"id":"de3b1a71-0b74-42e6-87b8-569689ad09da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03153410","created_at":"2025-02-25T16:06:15.779Z","updated_at":"2025-02-25T16:06:15.779Z","phase":"Phase 1","brief_title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT03153410","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 03/09/2022","primary_completion_date":" 03/09/2022","study_txt":" Completion: 08/29/2023","study_completion_date":" 08/29/2023","last_update_posted":"2025-01-09"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"}]